- 专利标题: Anti-TMEM-180 antibody, anticancer drug and cancer testing method
-
申请号: US16083077申请日: 2017-03-07
-
公开(公告)号: US11633499B2公开(公告)日: 2023-04-25
- 发明人: Yasuhiro Matsumura , Masahiro Yasunaga , Shinji Saijou , Shingo Hanaoka , Takahiro Anzai , Shino Manabe
- 申请人: NATIONAL CANCER CENTER JAPAN , RIN INSTITUTE INC.
- 申请人地址: JP Tokyo; JP Tokyo
- 专利权人: NATIONAL CANCER CENTER JAPAN,RIN INSTITUTE INC.
- 当前专利权人: NATIONAL CANCER CENTER JAPAN,RIN INSTITUTE INC.
- 当前专利权人地址: JP Tokyo; JP Tokyo
- 代理机构: Clark & Elbing LLP
- 代理商 Susan M. Michaud
- 优先权: JPJP2016-044946 20160308,JPJP2016-161697 20160822
- 国际申请: PCT/JP2017/008900 WO 20170307
- 国际公布: WO2017/154868 WO 20170914
- 主分类号: G01N33/574
- IPC分类号: G01N33/574 ; C07K16/30 ; A61K47/68 ; C12N15/09 ; C12N5/10 ; A61K39/395 ; A61K49/00 ; A61P35/00 ; C12N15/62
摘要:
An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.
公开/授权文献
信息查询
IPC分类: